GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arqule Inc (NAS:ARQL) » Definitions » PS Ratio

Arqule (Arqule) PS Ratio : 454.55 (As of Apr. 26, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Arqule PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Arqule's share price is $20.00. Arqule's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2019 was $0.04. Hence, Arqule's PS Ratio for today is 454.55.

The historical rank and industry rank for Arqule's PS Ratio or its related term are showing as below:

ARQL's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.92
* Ranked among companies with meaningful PS Ratio only.

Arqule's Revenue per Sharefor the three months ended in Sep. 2019 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2019 was $0.04.

Back to Basics: PS Ratio


Arqule PS Ratio Historical Data

The historical data trend for Arqule's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arqule PS Ratio Chart

Arqule Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.82 12.19 18.53 - 10.78

Arqule Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.61 10.78 21.67 125.11 162.95

Competitive Comparison of Arqule's PS Ratio

For the Biotechnology subindustry, Arqule's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arqule's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arqule's PS Ratio distribution charts can be found below:

* The bar in red indicates where Arqule's PS Ratio falls into.



Arqule PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Arqule's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=20.00/0.044
=454.55

Arqule's Share Price of today is $20.00.
Arqule's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Arqule  (NAS:ARQL) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Arqule PS Ratio Related Terms

Thank you for viewing the detailed overview of Arqule's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arqule (Arqule) Business Description

Traded in Other Exchanges
N/A
Address
One Wall Street, Burlington, MA, USA, 01803
Arqule Inc is a biopharmaceutical company, engaged in the research and development of therapeutics to treat cancers and rare diseases. The objective of the company is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of the patients. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Product portfolios of the group include Tivantinib, ARQ 087, ARQ 092, ARQ 761, and ARQ 751. Geographically, the firm operates through the region of United States.
Executives
Patrick J Zenner director C/O DENDRITE INTERNATIONAL INC., 1405/1425 ROUTE 206 SOUTH, BEDMINSTER NJ 07921
Marc Schegerin officer: CFO and Treasurer ARQULE INC, 1 WALL ST FL6, BURLINGTON MA 01803
Brian Schwartz officer: See Remarks C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Timothy C Barabe director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Susan L. Kelley director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Michael D Loberg director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Paolo Pucci director, officer: Chief Executive Officer C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Merck & Co., Inc. 10 percent owner 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Merck Sharp & Dohme Corp. 10 percent owner ONE MERCK DRIVE, WHITEHOUSE STATION NJ 08889
Robert J Weiskopf officer: Chief Financial Officer C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104